Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy RP2.

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...

Replimune (REPL) stock dips as the FDA plans an advisory committee meeting after accepting the company's marketing ...